세계의 프리필드시린지 시장 : 인사이트, 경쟁 환경, 시장 예측(-2032년)

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, increase impact of biologics and biosimilar on prefilled syringes, increase adoption of self-administration across the globe.

The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032. The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.

Prefilled Syringes Market Dynamics:

According to the recent data provided by the World Heart Organization (2023), about 528 million people globally were living with osteoarthritis.

Additionally, according to the recent data provided by the Institute for Health Metrics and Evaluation (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%.

Patients with osteoarthritis often need hyaluronic acid or corticosteroid injections for pain relief and joint mobility. Prefilled syringes provide a convenient and sterile method for administering these treatments in clinical and home settings, thus boosting the global prefilled syringe market. For example, Synvisc-One(R) manufactured by Genzyme Corporation, which is a subsidiary of Sanofi is a prefilled syringe that helps lubricate and cushion the knee joint, offering relief from osteoarthritis pain for up to six months.

Additionally, as per recent data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide were affected by multiple sclerosis. Multiple sclerosis impacted various functions, including cognitive, emotional, motor, sensory, and visual abilities, as the immune system mistakenly attacked the brain and spinal cord. Prefilled syringes were crucial for managing the condition, as they simplified dosing, reduced medication errors, and enhanced patient adherence to treatment regimens by offering a ready-to-use, accurate, and user-friendly delivery system. For instance, AVONEX is a once-weekly treatment for relapsing multiple sclerosis, provided as a 30 mcg intramuscular prefilled self-syringe.

Moreover, Biologics, including monoclonal antibodies, growth factors, and vaccines, are crucial for treating chronic conditions like cancer and autoimmune diseases. Administered via injection, prefilled syringes offer a convenient and accurate delivery method. Additionally, the rise of biosimilar generic versions of biologics has further propelled the demand for prefilled syringes, providing a more affordable treatment option.

For instance, in July 2024, Sandoz Group AG, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar Pyzchiva(R)* (ustekinumab-ttwe) in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, as well as a 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.

Thus, the factors mentioned above are expected to boost the overall market of prefilled syringes across the globe during the forecast period from 2025 to 2032.

However, increasing product recalls and failures due to safety issues and the availability of alternative products may hinder the future market of prefilled syringes across the globe during the forecasted period.

Prefilled Syringes Market Segment Analysis:

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The staked needle system category in the prefilled syringes market is estimated to dominate the market with a market share of 68.37% in 2024. The adoption of staked needle systems is significantly boosting the overall market of prefilled syringes by addressing key challenges in drug delivery and enhancing the usability, safety, and efficiency of injectable therapies. A staked needle system integrates the needle directly into the syringe barrel, eliminating the need for additional assembly, such as attaching a separate needle. This design simplifies the injection process, reduces preparation time, and minimizes the risk of needle-related complications, such as detachment or improper attachment, making it highly preferred in both clinical and self-administration settings.

One of the major drivers of the staked needle system's impact is its contribution to patient safety. The fixed-needle design reduces the risk of needle-stick injuries, which is a critical concern for healthcare professionals, especially in high-pressure environments like hospitals and emergency care. Additionally, the reduced dead space in staked needle systems ensures precise dosing and minimizes medication waste, which is particularly advantageous for high-cost biologics, vaccines, and specialty drugs. This attribute makes staked needle systems an ideal choice for administering small-volume, high-potency medications, aligning with the growing demand for precision medicine. The integration of staked needle systems into advanced prefilled syringes, such as autoinjectors and pen injectors, further boosts their appeal in the rapidly growing self-injection device market.

Pharmaceutical companies are increasingly adopting staked needle systems for their prefilled syringes due to their compatibility with a wide range of drugs, including biologics and biosimilars, which are gaining traction globally. The design ensures the sterility and integrity of the drug product, reducing the likelihood of contamination or degradation. Furthermore, staked needle systems are well-suited for high-speed, automated manufacturing processes, enabling efficient large-scale production while maintaining consistent quality, which aligns with the rising demand for prefilled syringes worldwide.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of prefilled syringes across the globe.

North America is expected to dominate the overall prefilled syringes market:

Among all regions, North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 53.2 million people (21.2%), had been diagnosed with arthritis and rheumatoid arthritis in the United States, between 2019 to 2021.

Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, it was stated that around 38.4 million, accounting for 11.6% of the US population was suffering from diabetes, in 2021. Chronic diseases like diabetes and rheumatoid arthritis require continuous treatment over the long term. Patients need regular injections to manage their conditions, often for the rest of their lives. Prefilled syringes make these daily treatments easier, and more accurate, and allow easy self-administration of medications at home.

Furthermore, the well-established patient care system along with high awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the United States prefilled syringes market growth.

Moreover, the increasing use of prefilled syringes highlights the rapid adoption of technologically advanced solutions, which is expected to drive market growth. For instance, in March 2024, Mallinckrodt plc. announced that the U.S. FDA approved the Acthar(R) Gel (repository corticotropin injection) Single-Dose SelfJect(TM) Injector, a new delivery device for Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. The SelfJect was designed to allow patients greater control over their medication administration.

Thus, the above-mentioned factors are expected to escalate the market of prefilled syringes in the region.

Prefilled Syringes Market Key Players:

Some of the key market players operating in the Prefilled Syringes market include BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

Recent Developmental Activities in the Prefilled Syringes Market:

• In March 2024, SCHOTT Pharma expanded in the U.S. with a new prefillable syringe manufacturing facility in Wilson, North Carolina with a $371 million investment.
• In May 2024, InvAscent, through India Life Sciences IV (ILSF IV), partnered with Morgan Stanley Private Equity Asia to invest INR 10,000 million in Maiva Pharma, recognized as India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds raised were intended to enhance vial, lyophilization, and suspension capacity, as well as to introduce new manufacturing capabilities, including prefilled syringes, cartridges, and bags.

Key Takeaways From the Prefilled Syringes Market Report Study

• Market size analysis for current prefilled syringes size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the prefilled syringes market.
• Various opportunities available for the other competitors in the prefilled syringes market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current prefilled syringes market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for prefilled syringes market growth in the coming future?

Target Audience Who Can be Benefited From This Prefilled Syringes Market Report Study

• Prefilled syringes product providers
• Research organizations and consulting companies
• Prefilled syringes-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in prefilled syringes
• Various end-users who want to know more about the prefilled syringes market and the latest technological developments in the prefilled syringes market.

Frequently Asked Questions for the Prefilled Syringes Market:

1. What are prefilled syringes?

• Prefilled syringes are medical devices that deliver medication in precise, pre-measured doses, ready for immediate use. These syringes filled with liquid medication have a securely attached needle, ensuring safety and eliminating the need for preparation.

2. What is the market for prefilled syringes?

• The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032.

3. What are the drivers for the global prefilled syringes market?

• The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global prefilled syringes market?

• Some of the key market players operating in the prefilled syringes are BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

5. Which region has the highest share in the global prefilled syringes market?

• North America region is anticipated to dominate the overall prefilled syringes market due to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.

Table of Contents

1. Prefilled Syringes Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Prefilled Syringes Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Prefilled Syringes Market Key Factors Analysis

• 5.1. Prefilled Syringes Market Drivers
  • 5.1.1. The increasing prevalence of chronic diseases
  • 5.1.2. Increase impact of biologics and biosimilar on prefilled syringes
  • 5.1.3. Increase adoption of self-administration across the globe
• 5.2. Prefilled Syringes Market Restraints and Challenges
  • 5.2.1. Increasing product recalls and failures due to safety issues
  • 5.2.2. Availability of alternative products
• 5.3. Prefilled Syringes Market Opportunities
  • 5.3.1. Increased funding and investment for more extensive research and development activities

6. Prefilled Syringes Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Prefilled Syringes Market Assessment

• 7.1. By Product Type
  • 7.1.1. Staked Needle System
  • 7.1.2. Luer Cone System
  • 7.1.3. Luer Lock System
• 7.2. By Material
  • 7.2.1. Glass
  • 7.2.2. Plastic
• 7.3. By Type
  • 7.3.1. With Needle
  • 7.3.2. Without Needle
• 7.4. By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Online Pharmacies
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.1.2. Canada Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.1.3. Mexico Prefilled Syringes Market Size in USD Million (2022-2032)
  • 7.5.2. Europe
    • 7.5.2.1. France Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2.2. Germany Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2.3. United Kingdom Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2.4. Italy Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2.5. Spain Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2.6. Rest of Europe Prefilled Syringes Market Size in USD Million (2022-2032)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3.2. Japan Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3.3. India Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3.4. Australia Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3.5. South Korea Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3.6. Rest of Asia-Pacific Prefilled Syringes Market Size in USD Million (2022-2032)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.4.2. Africa Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.4.3. South America Prefilled Syringes Market Size in USD Million (2022-2032)

8. Prefilled Syringes Market Company and Product Profiles

• 8.1. BD
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Nipro Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Taisei Kako Co., Ltd.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Terumo Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. SCHOTT Pharma AG & Co. KGaA
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Gerresheimer AG
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Johnson and Johnson Services, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Dali Medical Devices
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Stevanato Groupand
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Credence MedSystems, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Baxter
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. MAEDA INDUSTRY Co., Ltd.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. MedXL, Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Sanofi
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Sandoz AG
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Pfizer Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. B. Braun Melsungen AG
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Novartis AG
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Fresenius SE & Co. KGaA
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Cardinal Health
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us